Using LED light to treat skin discoloration
The Therapeutic and Preventive Effects of Light-emitting Diodes (LEDs) Irradiation for Post-inflammatory Erythema and Hyperpigmentation: a Self-controlled
This study tests if LED light therapy can help reduce skin discoloration caused by inflammation in healthy adults aged 20-65.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06349447 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 830 nm and 590 nm LED phototherapies in preventing and treating post-inflammatory erythema (PIE) and post-inflammatory hyperpigmentation (PIH). Healthy participants aged 20-65 with specific skin types will undergo LED treatments after inducing skin discoloration. The study will measure changes in skin conditions using various indices and photography over a 10-day follow-up period. The goal is to gather evidence on the efficacy of LED light therapy for these skin conditions.
Who should consider this trial
Good fit: Ideal candidates are healthy Asian individuals aged 20-65 with Fitzpatrick skin types III-IV.
Not a fit: Patients with abnormal skin conditions, systemic diseases, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for patients suffering from skin discoloration due to inflammation.
How similar studies have performed: While evidence on LED efficacy for PIE and PIH is limited, similar photobiomodulation approaches have shown promise in other dermatological applications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Healthy Asians; 2. 20-65 years old; 3. Fitzpatrick classification III-IV; 4. Sign the informed consent form. Exclusion Criteria: 1. Have abnormal skin manifestations, such as pigment diseases, photosensitivity diseases and other allergic diseases; 2. Those with a history of abnormal systemic diseases, such as heart disease, liver disease, kidney disease, tumors, and mental illness; 3. Women who are preparing for pregnancy, pregnant or breastfeeding; 4. Have used photosensitizing drugs within two weeks before inclusion in this study; 5. Topical or systemic drugs may be used during this study; 6. bad habits, such as smoking, drinking, etc.; 7. Volunteers who have recently participated in other clinical trials;
Where this trial is running
Shanghai
- Huashan Hospital — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Leihong Xiang, professor — Huashan Hospital
- Study coordinator: Yanjun Dan
- Email: danyanjun@126.com
- Phone: +86 159 0194 0897
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.